TOP > 外国特許検索 > CONDITIONALLY REPLICATING ADENOVIRUS EXPRESSING REIC GENE

CONDITIONALLY REPLICATING ADENOVIRUS EXPRESSING REIC GENE

外国特許コード F160008748
整理番号 S2014-1019-C0
掲載日 2016年5月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP065004
国際公開番号 WO 2015182574
国際出願日 平成27年5月26日(2015.5.26)
国際公開日 平成27年12月3日(2015.12.3)
優先権データ
  • 特願2014-110672 (2014.5.28) JP
発明の名称 (英語) CONDITIONALLY REPLICATING ADENOVIRUS EXPRESSING REIC GENE
発明の概要(英語) The purpose is to provide a conditionally replicating adenovirus having a strong anticancer effect. A conditionally replicating adenovirus growing specifically in cancer cells and expressing an REIC protein or REIC C domain protein, having full-length REIC DNA or REIC C domain DNA inserted into a conditionally replicating adenovirus including an (inverted terminal repeat) ITR sequence of a type 5 adenovirus and having an HRE sequence, hTERT promoter, DNA encoding decorin, and DNA encoding a peptide including an RGD sequence inserted.
従来技術、競合技術の概要(英語) BACKGROUND ART
So far, proliferation type (cancer cell-specific proliferation of the genetically modified) virus for cancer using a medicament drug in a clinical have been reported (non-patent document 1). These agents in the treatment of cancer is increasing constant result on the other hand, the effect is limited in many cases, a more effective has been desired the development of a drug.
The results of clinical trials to date have been reported using medicaments against cancer proliferation-type virus as a representative example of, adenovirus type 5 Telomelysin backbone (non-patent document 2) and herpes simplex virus type 1 Oncovex old Talimogene laherparepvec(T-VEC, backbone) (non-patent document 3) is.
In recent years, as shown in non-patent document 1, for each virus using medicaments against cancer, anti-cancer immune activation is important to have such a function has been been considered. From this point of view, for (non-patent document 2) Telomelysin, anti-cancer immune activating cytokines such as encoded by the gene is not, the local administration of the adenovirus Telomelysin in the growth of cancer by induction of cell death can be of, systemic potent anti-cancer immune activation effect cannot be expected. This, limiting the therapeutic effect of Telomelysin has been applied to the can.
In addition, for T-VEC, the local administration of a herpesvirus by growing in cancer cell death, and a reduction in the cytokine GM-CSF antigen of cancer cells by expression of anti-cancer immune activation can be expected. However cytokine GM-CSF is, cancer antigen presenting cell to induce the differentiation of dendritic cells that in addition to the action of anti-cancer immune activation (non-patent document 1), at the high dose anti-cancer immune suppressing system induces attenuated immune function, potentially exacerbating the disease condition also reported (non-patent document 4) and, the therapeutic effect of this T-VEC limiting has been applied to the can.
That is, using the existing proliferation-type virus medicaments against cancer taking into account of these problems, the more effective has been desired the development of a drug. In order to solve the above problems and various kinds of proliferation-type adenovirus contains a mutation of proliferation-type adenovirus has been reported (Patent Document 1 and 2 and non-patent document 5-10).
On the other hand, as genes associated with immortalization of cells, REIC gene (REIC/Dkk-3) are known, the expression of this gene in cancer cells reported to be suppressed and, used to treat cancer REIC gene have been reported (patent document 3). The effect of activating REIC anticancer immunity, cancer cells gene expression at the time of the endoplasmic reticulum and having a function for induce cell death. In addition, a portion of the gene of the full-length REIC REIC fragment has the same effect is also reported (patent document 4), adenovirus expressing further REIC/Dkk-3 gene has been reported to have (patent document 5 and non-patent document 11).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • MOMOTARO-GENE INC.
  • INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
  • 発明者(英語)
  • KUMON Hiromi
  • NASU Yasutomo
  • WATANABE Masami
  • YUN Chae Ok
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close